## Otis W Brawley

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9590519/publications.pdf

Version: 2024-02-01

50 6,357 25
papers citations h-index

46 g-index

50 50 all docs citations

50 times ranked 10155 citing authors

#	Article	IF	CITATIONS
1	Colorectal cancer screening for averageâ€risk adults: 2018 guideline update from the American Cancer Society. Ca-A Cancer Journal for Clinicians, 2018, 68, 250-281.	329.8	1,287
2	Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. Ca-A Cancer Journal for Clinicians, 2018, 68, 31-54.	329.8	970
3	Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2017, 67, 100-121.	329.8	529
4	How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials. Journal of Clinical Oncology, 2002, 20, 2109-2117.	1.6	461
5	Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2018, 68, 297-316.	329.8	433
6	Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2054.	7.4	382
7	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372
8	Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2016, 66, 95-114.	329.8	198
9	Cancer statistics: Breast cancer in situ. Ca-A Cancer Journal for Clinicians, 2015, 65, 481-495.	329.8	184
10	An assessment of progress in cancer control. Ca-A Cancer Journal for Clinicians, 2018, 68, 329-339.	329.8	145
11	Comparison of Insurance Status and Diagnosis Stage Among Patients With Newly Diagnosed Cancer Before vs After Implementation of the Patient Protection and Affordable Care Act. JAMA Oncology, 2018, 4, 1713.	7.1	135
12	Equitably improving outcomes for cancer survivors and supporting caregivers: A blueprint for care delivery, research, education, and policy. Ca-A Cancer Journal for Clinicians, 2019, 69, 35-49.	329.8	124
13	Cancer screening in the United States, 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 129-142.	329.8	123
14	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	10.7	94
15	The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections. Ca-A Cancer Journal for Clinicians, 2016, 66, 359-369.	329.8	88
16	A blueprint for cancer screening and early detection: Advancing screening's contribution to cancer control. Ca-A Cancer Journal for Clinicians, 2019, 69, 50-79.	329.8	84
17	Minimizing the burden of cancer in the United States: Goals for a highâ€performing health care system. Ca-A Cancer Journal for Clinicians, 2019, 69, 166-183.	329.8	69
18	Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening. JAMA Oncology, 2016, 2, 1657.	7.1	64

#	Article	IF	Citations
19	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 2021, 7, 412.	7.1	63
20	Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Journal of Clinical Oncology, 2017, 35, 3075-3082.	1.6	62
21	Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Ca-A Cancer Journal for Clinicians, 2017, 67, 353-361.	329.8	49
22	The American Cancer Society 2035 challenge goal on cancer mortality reduction. Ca-A Cancer Journal for Clinicians, 2019, 69, 351-362.	329.8	49
23	A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. Ca-A Cancer Journal for Clinicians, 2018, 68, 446-470.	329.8	42
24	American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. Journal of Clinical Oncology, 2017, 35, 2576-2579.	1.6	41
25	Recent Patterns of Prostate-Specific Antigen Testing for Prostate Cancer Screening in the United States. JAMA Internal Medicine, 2017, 177, 1040.	5.1	39
26	Disparities in Breast Cancer. Obstetrics and Gynecology Clinics of North America, 2022, 49, 149-165.	1.9	32
27	The first surgeon general's report on smoking and health: The 50th anniversary. Ca-A Cancer Journal for Clinicians, 2014, 64, 5-8.	329.8	27
28	Racial Inequality in Prostate Cancer Outcomesâ€"Socioeconomics, Not Biology. JAMA Oncology, 2019, 5, 983.	7.1	26
29	How many individuals will need to be screened to increase colorectal cancer screening prevalence to 80% by 2018?. Cancer, 2015, 121, 4258-4265.	4.1	24
30	Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States. Annals of Family Medicine, 2018, 16, 139-144.	1.9	21
31	The role of government and regulation in cancer prevention. Lancet Oncology, The, 2017, 18, e483-e493.	10.7	18
32	Health inequity drives disease biology to create disparities in prostate cancer outcomes. Journal of Clinical Investigation, $2022,132,$ .	8.2	17
33	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature Medicine, 2022, 28, 620-626.	30.7	13
34	The history of cancer screening. Current Problems in Surgery, 2019, 56, 138-163.	1.1	12
35	Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. Journal of the National Cancer Institute, 2022, 114, 191-202.	<b>6.</b> 3	12
36	Prostate Cancer Screening: Biases and the Need for Consensus. Journal of the National Cancer Institute, 2013, 105, 1522-1524.	6.3	11

#	Article	IF	CITATIONS
37	Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non–Small-Cell Lung Cancer. JCO Global Oncology, 2021, 7, 1537-1546.	1.8	8
38	Breast cancer screening: Time for rational discourse. Cancer, 2014, 120, 2800-2802.	4.1	7
39	Overdiagnosis in the Age of Digital Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 1-2.	6.3	7
40	Prostate cancer and the social construct of race. Cancer, 2021, 127, 1374-1376.	4.1	7
41	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. Value in Health, 2022, 25, 796-802.	0.3	6
42	Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e13-195.e18.	1.6	6
43	Toward the control of cancer. Ca-A Cancer Journal for Clinicians, 2018, 68, 327-328.	329.8	5
44	The 50 years' war: The history and outcomes of the National Cancer Act of 1971. Cancer, 2021, 127, 4534-4540.	4.1	5
45	DeImplementing Ineffective and Low-Value Clinical Practices: Research and Practice Opportunities in Community Oncology Settings. JNCI Cancer Spectrum, 2021, 5, pkab020.	2.9	4
46	The Realities of Prostate Cancer Screening, Treatment, and Race. Journal of the National Cancer Institute, 2021, 113, 1272-1273.	6.3	2
47	Epilogue. Journal of the National Cancer Institute Monographs, 2012, 2012, 134-134.	2.1	0
48	Editorial Comment. Urology, 2015, 86, 504.	1.0	0
49	The avoidable casualties in America's war on cancer. Cancer, 2021, 127, 2390-2392.	4.1	0
50	On the Black–White Disparity in Prostate Cancer Mortality. JNCI Cancer Spectrum, 2022, 6, pkab094.	2.9	0